WO1999006550B1 - 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE - Google Patents
5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATEInfo
- Publication number
- WO1999006550B1 WO1999006550B1 PCT/IB1998/001232 IB9801232W WO9906550B1 WO 1999006550 B1 WO1999006550 B1 WO 1999006550B1 IB 9801232 W IB9801232 W IB 9801232W WO 9906550 B1 WO9906550 B1 WO 9906550B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nos
- cdna
- sequences
- nucleic acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 18
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 16
- 210000002307 prostate Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 15
- 108020004414 DNA Proteins 0.000 claims abstract 6
- 238000011144 upstream manufacturing Methods 0.000 claims abstract 5
- 108020004999 messenger RNA Proteins 0.000 claims abstract 4
- 239000013604 expression vector Substances 0.000 claims abstract 3
- 239000002299 complementary DNA Substances 0.000 claims 38
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 230000000295 complement effect Effects 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 102000040739 Secretory proteins Human genes 0.000 claims 9
- 108091058545 Secretory proteins Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000005026 transcription initiation Effects 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 abstract 1
- 238000003200 chromosome mapping Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000013606 secretion vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.
Claims
1. A purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs; 38-315 or comprising a sequence complementary thereto.
2. The nucleic acid of Claim 1, wherein said nucleic acid is recombinant.
3. A purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 38-315 or one of the sequences complementary thereto, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
4. A purified or isolated nucleic acid comprising at least 15 consecutive bases of one of the sequences of SEQ ID NOs: 38-315 or one of the sequences complementary thereto, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
5. The nucleic acid of Claim 4, wherein said nucleic acid is recombinant.
6. A purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 38-315 or one of the sequences complementary to the sequences of SEQ ID NOs: 38-315, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
7. The nucleic acid of Claim 6, wherein said nucleic acid is recombinant.
8. A purified or isolated nucleic acid encoding a human gene product, said human gene product having a sequence partially encoded by one of the sequences of SEQ ID
NOs: 38-315, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
9. A purified or isolated nucleic acid having the sequence of one of SEQ ID NOs: 38-315 or having a sequence complementary thereto.
10. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 38- 15 which encode a signal peptide.
11. A purified or isolated polypeptides comprising a signal peptide encoded by one of the sequences of SEQ ED NOs: 38-315.
12. A vector encoding a fusion protein comprising a polypeptide and a signal peptide, said vector comprising a first nucleic acid encoding a signal peptide encoded by one of the sequences of SEQ ID NOs: 38-315 operably linked to a second nucleic acid encoding a polypeptide.
13. A method of directing the extracellular secretion of a polypeptide or the insertion of a polypeptide into the membrane comprising the steps of: obtaining a vector according to Claim 12; and introducing said vector into a host cell such that said fusion protein is secreted into the extracellular environment of said host cell or inserted into the membrane of said host cell.
14. A method of importing a polypeptide into a cell comprising contacting said cell with a fusion protein comprising a signal peptide encoded by one of the sequences of
SEQ ID NOs: 38-315 operably linked to said polypeptide.
15. A method of making a cDNA encoding a human secretory protein that is partially encoded by one of SEQ ID NOs 38-315, comprising the steps of: obtairώig a cDNA comprising one of the sequences of SEQ ID NOs: 38-315; contacting said cDNA with a detectable probe comprising at least 15 consecutive nucleotides of said sequence of SEQ ID NOs: 38-315 or a sequence complementary thereto under conditions which permit said probe to hybridize to said cDNA; identifying a cDNA which hybridizes to said detectable probe; and isolating said cDNA which hybridizes to said probe.
16. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-315 or a fiagment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 15.
17. The cDNA of Claim 16 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
18. A method of making a cDNA comprising one o the sequences of SEQ ID NOs: 38-315, comprising the steps of: contacting a collection of mRNA molecules from human cells with a first primer capable of hybridizing to the polyA tail of said mRNA; hybridizing said first primer to said polyA tail; reverse transcribing said mRNA to make a first cDNA strand; making a second cDNA strand complementary to said first cDNA strand using at least one primer comprising at least IS nucleotides of one ofthe sequences of SEQ ID NOs 38-315; and isolating the resulting cDNA comprising said first cDNA strand and said second cDNA strand.
19. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38- 15 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 18.
20. The cDNA of Claim 19 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
21. The method of Claim 18, wherein the second cDNA strand is made by; contacting said first cD A strand with a first pair of primers, said first pair of primers comprising a second primer comprising at least 15 consecutive nucleotides of one of the sequences of SEQ ID NOs 38-315 and a third primer having a sequence therein which is included within the sequence of said first primer; perfbπriing a first polymerase chain reaction with said first pair of nested primers to generate a first PCR product; contacting said first PCR product with a second pair of primers, said second pair of primers comprising a fourth primer, said fourth primer comprising at least 15 consecutive nucleotides of said sequence of one of SEQ ID NOs: 38-315, and a fifth primer, said fourth and fifth primers being capable of hybridizing to sequences within said first PCR product; and performing a second polymerase chain reaction, thereby generating a second PCR product.
1 38
22. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ED NOs; 38-315, or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 21.
23. The cDNA of Claim 22 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
24. The method of Claim 18 wherein the second cDNA strand is made by: contacting said first cDNA strand with a second primer comprising at least 15 consecutive nucleotides ofthe sequences of SEQ ID NOs: 38-315; hybridizing said second primer to said first strand cDNA; and extending said hybridized second primer to generate said second cDNA strand.
25. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein partially encoded by one of SEQ ID NOs; 38-315 or comprising a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 24.
26. The cDNA of Claim 25, wherein said cDNA comprises the full protein coding sequence partially included in of one ofthe sequences of SEQ ID NOs: 38-315.
27. A method of making a protein comprising one of the sequences of SEQ ID NOs; 316-593, comprising the steps of: obtaining a cDNA encoding the full protein sequence partially included in one ofthe sequences of sequence of SEQ ID NOs: 38-315; inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter; introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA; and isolating said protein.
28. An isolated protein obtainable by the method of Claim 27.
29. A method of obtaining a promoter DNA comprising the steps of: obtaining DNAs located upstream ofthe nucleic acids of SEQ ID NOs: 38-315 or the sequences complementary thereto;
139
screening said upstream DNAs to identify a promoter capable of directing transcription initiation; and isolating said DNA comprising said identified promoter.
30. The method of Claim 29, wherein said obtaining step comprises chromosome walking from said nucleic acids of SEQ ID NOs: 38-315 or sequences complementary thereto.
31. The method of Claim 30, wherein said screening step comprises inserting said upstream sequences into a promoter reporter vector.
32. The method of Claim 30, wherein said screening step comprises identifying motifs in said upstream DNAs which are transcription factor binding sites or transcription start sites.
33. An isolated promoter obtainable by the method of Claim 32.
34. An isolated or purified protein comprising one ofthe sequences of SEQ ID NOs: 316-593.
35. In an array of discrete ESTs or fragments thereof of at least 15 nucleotides in length, the improvement comprising inclusion in said array of at least one ofthe sequences of SEQ ID NOs; 38-315, or one ofthe sequences complementary to the sequences of SEQ ID NOs: 38-315, or a fragment thereof of at least 15 consecutive nucleotides.
36. The array of Claim 35 including therein at least two ofthe sequences of SEQ ID NOs: 38-315, the sequences complementary to the sequences of SEQ ID NOs: 38-315, or fragments thereof of at least 15 consecutive nucleotides.
37. The array of Claim 35 including therein at least five ofthe sequences of SEQ ID NOs; 38-315, the sequences complementary to the sequences of SEQ ID NOs: 38-315, or fragments thereof of at least 15 consecutive nucleotides.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002296287A CA2296287A1 (en) | 1997-08-01 | 1998-07-31 | 5' ests for secreted proteins expressed in prostate |
| EP98936590A EP1000148A2 (en) | 1997-08-01 | 1998-07-31 | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE |
| AU85551/98A AU8555198A (en) | 1997-08-01 | 1998-07-31 | 5' ests for secreted proteins expressed in prostate |
| JP2000505291A JP2001512013A (en) | 1997-08-01 | 1998-07-31 | 5'EST of secreted protein expressed in prostate |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90514497A | 1997-08-01 | 1997-08-01 | |
| US08/905,144 | 1997-08-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999006550A2 WO1999006550A2 (en) | 1999-02-11 |
| WO1999006550A3 WO1999006550A3 (en) | 1999-04-29 |
| WO1999006550B1 true WO1999006550B1 (en) | 1999-06-03 |
Family
ID=25420349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1998/001232 WO1999006550A2 (en) | 1997-08-01 | 1998-07-31 | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1000148A2 (en) |
| JP (1) | JP2001512013A (en) |
| AU (1) | AU8555198A (en) |
| CA (1) | CA2296287A1 (en) |
| WO (1) | WO1999006550A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306796B2 (en) | 1999-04-12 | 2007-12-11 | Agensys, Inc. | 13-transmembrane protein expressed in prostate cancer |
| US11932678B2 (en) | 2015-07-06 | 2024-03-19 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6656480B2 (en) * | 1996-01-11 | 2003-12-02 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| WO2000075327A1 (en) * | 1999-06-02 | 2000-12-14 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6261562B1 (en) | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6613872B1 (en) | 1997-02-25 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6262245B1 (en) | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US20030054987A1 (en) | 1997-06-16 | 2003-03-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
| CA2316182A1 (en) * | 1998-02-09 | 1999-08-12 | Genset S.A. | Cdnas encoding secreted proteins |
| AU2003262114B8 (en) * | 1998-02-09 | 2006-08-03 | Serono Genetics Institute S.A. | cDNAs encoding secreted proteins |
| US7049063B2 (en) | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
| US6660838B1 (en) | 1998-03-18 | 2003-12-09 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6365369B1 (en) | 1998-04-01 | 2002-04-02 | Human Genome Sciences, Inc. | Prostate specific secreted protein |
| GB9807723D0 (en) * | 1998-04-08 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| DE19818620A1 (en) * | 1998-04-21 | 1999-10-28 | Metagen Gesellschaft Fuer Genomforschung Mbh | New polypeptides and their nucleic acids, useful for treatment of bladder tumor and identification of therapeutic agents |
| US20020192751A1 (en) | 1998-05-15 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU3952699A (en) * | 1998-05-19 | 1999-12-06 | Compugen Ltd. | Metabotropic glutamate receptor-like protein and encoding cdna |
| JP4855577B2 (en) | 1998-06-01 | 2012-01-18 | アジェンシス，インコーポレイテッド | Novel serpentine transmembrane antigen expressed in human cancer and use thereof |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| AU761340B2 (en) * | 1998-06-02 | 2003-06-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| US7264801B2 (en) | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| AU5447899A (en) * | 1998-09-03 | 2000-03-27 | Takeda Chemical Industries Ltd. | Novel protein and process for producing the same |
| CA2342833A1 (en) * | 1998-09-17 | 2000-03-23 | Incyte Pharmaceuticals, Inc. | Human gpcr proteins |
| EP1632499B9 (en) * | 1999-03-08 | 2008-02-20 | Genentech, Inc. | Gene sequences amplified in tumours and their diagnostic uses |
| ES2314521T3 (en) | 1999-03-23 | 2009-03-16 | Genentech, Inc. | SECRETED AND TRANSMEMBRANE POLIPEPTIDES AND NUCLEIC ACIDS THAT CODIFY THEM. |
| EP1792989A1 (en) * | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
| US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
| JP2002541800A (en) * | 1999-04-12 | 2002-12-10 | アジェンシス， インコーポレイテッド | 13 transmembrane proteins expressed in prostate cancer |
| US20060073150A1 (en) | 2001-09-06 | 2006-04-06 | Mary Faris | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| JP2004522402A (en) * | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2003501072A (en) * | 1999-06-07 | 2003-01-14 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 26 human secreted proteins |
| US7033780B1 (en) | 1999-06-14 | 2006-04-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
| US20030022279A1 (en) | 1999-06-14 | 2003-01-30 | Fraser Christopher C. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| EP1194545A2 (en) * | 1999-06-23 | 2002-04-10 | Curagen Corporation | Secreted polypeptides and corresponding polynucleotides |
| US6951738B2 (en) | 1999-07-16 | 2005-10-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors TR13 and TR14 |
| JP2003505045A (en) * | 1999-07-16 | 2003-02-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Human tumor necrosis factor receptors TR13 and TR14 |
| WO2001010902A2 (en) * | 1999-08-11 | 2001-02-15 | Curagen Corporation | Nucleoc acids and secreted polypeptides encoded thereby |
| JP2003531571A (en) * | 1999-09-13 | 2003-10-28 | キュラジェン コーポレイション | Novel human proteins, polynucleotides encoding them, and methods of using them |
| US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| DK1220913T3 (en) * | 1999-10-05 | 2009-03-16 | Agensys Inc | G protein coupled receptor up-regulated in prostate cancer and its uses |
| US7208280B2 (en) | 1999-10-05 | 2007-04-24 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| US6835822B1 (en) | 1999-10-28 | 2004-12-28 | Agensys, Inc. | Diagnosis and therapy of cancer using SGP28-related molecules |
| EP1598671A1 (en) * | 1999-10-28 | 2005-11-23 | Agensys, Inc. | Diagnosis and therapy of cancer using SGP28-related molecules |
| US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
| FR2800388A1 (en) * | 1999-10-29 | 2001-05-04 | Pf Medicament | CLONING, EXPRESSION AND CHARACTERIZATION OF A GENE EXPRESSED IN TUMOR CELLS AND INVOLVED IN REGULATION OF THE IMMUNE RESPONSE |
| EP1230362A2 (en) * | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Human zven proteins |
| US6485938B1 (en) | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
| US20020037513A1 (en) * | 2000-03-24 | 2002-03-28 | Rosana Kapeller-Libermann | 33338, a novel human ubiquitin hydrolase-like molecule and uses thereof |
| KR100961345B1 (en) * | 2000-06-23 | 2010-06-04 | 제넨테크, 인크. | EV-VEEP nucleic acids and polypeptides and methods of use |
| EP1302542B1 (en) | 2000-07-18 | 2007-06-13 | Takeda Pharmaceutical Company Limited | Novel physiologically active peptide and use thereof |
| US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20040072293A1 (en) * | 2001-02-02 | 2004-04-15 | Tetsuya Ohtaki | Novel physiologically active peptide and use thereof |
| AUPR311601A0 (en) * | 2001-02-15 | 2001-03-08 | Adp Pharmaceutical Pty Limited | Matrix gene expression in chondrogenesis |
| US7070584B2 (en) | 2001-02-20 | 2006-07-04 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7927597B2 (en) | 2001-04-10 | 2011-04-19 | Agensys, Inc. | Methods to inhibit cell growth |
| AU2002318112B2 (en) | 2001-04-10 | 2007-12-06 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| US7291589B2 (en) | 2002-10-07 | 2007-11-06 | Zymogenetics, Inc. | Uses of human Zven proteins and polynucleotides |
| EP1565200A4 (en) * | 2002-11-27 | 2009-06-24 | Agensys Inc | Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer |
| NZ541480A (en) | 2003-03-12 | 2008-03-28 | Genentech Inc | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| MXPA06012187A (en) | 2004-04-22 | 2007-03-28 | Agensys Inc | Antibodies and molecules derived therefrom that bind to steap-1 proteins. |
| FR2982860B1 (en) * | 2011-11-18 | 2015-07-10 | Ass Fr Contre Les Myopathies | USE OF FIBROMODULIN AND LUMICAN TO INCREASE MUSCLE MASS |
| GB201511792D0 (en) * | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| PE20200010A1 (en) | 2017-04-03 | 2020-01-06 | Hoffmann La Roche | ANTIBODIES THAT JOIN STEAP-1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279582A3 (en) * | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3337748B2 (en) * | 1992-09-25 | 2002-10-21 | 財団法人神奈川科学技術アカデミー | Method for synthesizing full-length cDNA, method for producing intermediate thereof, and method for producing recombinant vector containing full-length cDNA |
| FR2733762B1 (en) * | 1995-05-02 | 1997-08-01 | Genset Sa | METHOD FOR THE SPECIFIC COUPLING OF THE HAIR OF THE 5 'END OF A RNAM FRAGMENT AND PREPARATION OF RNAM AND COMPLETE DNA |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
-
1998
- 1998-07-31 WO PCT/IB1998/001232 patent/WO1999006550A2/en not_active Application Discontinuation
- 1998-07-31 CA CA002296287A patent/CA2296287A1/en not_active Abandoned
- 1998-07-31 AU AU85551/98A patent/AU8555198A/en not_active Abandoned
- 1998-07-31 EP EP98936590A patent/EP1000148A2/en not_active Ceased
- 1998-07-31 JP JP2000505291A patent/JP2001512013A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306796B2 (en) | 1999-04-12 | 2007-12-11 | Agensys, Inc. | 13-transmembrane protein expressed in prostate cancer |
| US11932678B2 (en) | 2015-07-06 | 2024-03-19 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
| US11939366B2 (en) | 2015-07-06 | 2024-03-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
| US11999774B2 (en) | 2015-07-06 | 2024-06-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
| US12258382B2 (en) | 2015-07-06 | 2025-03-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999006550A3 (en) | 1999-04-29 |
| WO1999006550A2 (en) | 1999-02-11 |
| CA2296287A1 (en) | 1999-02-11 |
| EP1000148A2 (en) | 2000-05-17 |
| AU8555198A (en) | 1999-02-22 |
| JP2001512013A (en) | 2001-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999006550B1 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE | |
| WO1999006552B1 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN | |
| WO1999006548B1 (en) | 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS | |
| WO1999006554B1 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES | |
| WO1999006551B1 (en) | 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES | |
| WO1999006553B1 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES | |
| US5695937A (en) | Method for serial analysis of gene expression | |
| Chu et al. | Cloning and characterization of five overlapping cDNAs specific for the human proα 1 (I) collagen chain | |
| CA2336227A1 (en) | Genes involved in tolerance to environmental stress | |
| Astell et al. | The sequence of the DNAs coding for the mating-type loci of Saccharomyces cerevisiae | |
| JP3334806B2 (en) | Sequential analysis of gene expression | |
| Sokolov et al. | A rapid and simple PCR-based method for isolation of cDNAs from differentially expressed genes | |
| Konecki et al. | Hypoxanthine-guanine phosphoribosyltransferase genes of mouse and Chinese hamster: construction and sequence analysis of cDNA recombinants | |
| Indik et al. | Structure of the 3’region of the human elastin gene: great abundance of Alu repetitive sequences and few coding sequences | |
| Sümegi et al. | A hierarchic arrangement of the repetitive sequences in the Balbiani ring 2 gene of Chironomus tentans | |
| DE69839426D1 (en) | NUCLEOTIDE SEQUENCES CODING FOR SECRETATED POLYPEPTIDES FROM MYCOBACTERIUM, VECTORS CONTAINING THEM, AND APPLICATIONS FOR THE DIAGNOSIS AND PREVENTION OF TUBERCULOSIS | |
| CA2118071A1 (en) | Dna encoding limonene synthase from mentha spicata | |
| ATE312929T1 (en) | NUCLEOTIDE SEQUENCES CODING FOR THE MDHA GENE FROM CORYNEBACTERIUM GLUTAMICUM | |
| Cooley et al. | Multiple combinations of alternatively spliced exons in rat tropomyosin-α gene mRNA: evidence for 20 new isoforms in adult tissues and cultured cells | |
| WO2000000607B1 (en) | A nucleic acid encoding a retinoblastoma binding protein (rbp-7) and polymorphic markers associated with said nucleic acid | |
| Ajioka et al. | The calmodulin-ubiquitin associated genes of Trypanosoma cruzi: their identification and transcription | |
| CA2573022A1 (en) | Novel sequence for improving expression of nucleic acid | |
| JP2001516764A5 (en) | ||
| WO2000066722B1 (en) | Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof | |
| Simmler et al. | Localization and expression analysis of a novel conserved brain expressed transcript, Brx/BRX, lying within the Xic/XIC candidate region |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| ENP | Entry into the national phase in: |
Ref country code: CA Ref document number: 2296287 Kind code of ref document: A Format of ref document f/p: F Ref document number: 2296287 Country of ref document: CA |
|
| NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 85551/98 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998936590 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998936590 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1998936590 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998936590 Country of ref document: EP |